ENJPY yields 2.74% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 10
Combined, ENJPY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ENJPY + JNJ for your $10,000?
en-japan inc. provides online recruitment, recruiting and staffing, employee training, and HR consulting and aptitude test services in Japan and internationally. The company operates job information sites, including en TENSHOKU for various recruitment and career change support services; en TENSHOKU WOMAN, a career-change support services for women; AMBI, a career change site designed for young people; MIDDLE NO TENSHOKU, a recruitment website; en HAKEN, a job-search site for temporary employment; en BAITO, a recruitment website for part-time and casual job information; en WOMEN WORK, a recruitment site for women professionals; and ONNA NO KYUJIN MART, a centralized recruitment site for female professionals. It also provides recruiting services, such as en AGENTS that offers professional and specialized support services; en Lighthouse, a word-of-mouth site; CAREER HACK, a career information site for professionals in web and IT industries; and SMART GYOKAI MAP, an industry research site that explains various companies and trends in specific industries. In addition, the company operates en JINJI NO MIKATA, a recruitment support services for HR professionals; en COLLEGE for employee education services; engage, a website for recruitment support tool; HR OnBoard, an employee retention risk identification tool; and 3E TEST for assessing the talent pool, as well as provides evaluation and education consulting services. The company was founded in 2000 and is based in Tokyo, Japan.
Full ENJPY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.